• Abionyx Pharma entered a strategic partnership with Texcell, an ABL Diagnostics unit, to run viral safety and clearance studies for CER-001.
• Work supports process-validation manufacturing batches, a key industrial and regulatory step toward a potential LCAT deficiency launch.
• Studies aim to demonstrate the CER-001 manufacturing process can inactivate or remove potential viral contaminants to meet global regulatory standards.
• Collaboration fits a wider France-based industrialization program intended to secure scalable production conditions for future commercialization of CER-001.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abionyx Pharma SA published the original content used to generate this news brief on September 10, 2026, and is solely responsible for the information contained therein.